PH12018501280A1 - Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use - Google Patents
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of useInfo
- Publication number
- PH12018501280A1 PH12018501280A1 PH12018501280A PH12018501280A PH12018501280A1 PH 12018501280 A1 PH12018501280 A1 PH 12018501280A1 PH 12018501280 A PH12018501280 A PH 12018501280A PH 12018501280 A PH12018501280 A PH 12018501280A PH 12018501280 A1 PH12018501280 A1 PH 12018501280A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- myostatin antibodies
- regions
- polypeptides containing
- nucleic acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015247070 | 2015-12-18 | ||
| PCT/JP2016/087487 WO2017104783A1 (en) | 2015-12-18 | 2016-12-16 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018501280A1 true PH12018501280A1 (en) | 2019-01-28 |
Family
ID=59011957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018501280A PH12018501280A1 (en) | 2015-12-18 | 2018-06-14 | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3390443A4 (en) |
| JP (4) | JP6142069B1 (en) |
| KR (3) | KR101820637B1 (en) |
| CN (2) | CN108473562B (en) |
| AR (1) | AR107078A1 (en) |
| AU (1) | AU2016372934B2 (en) |
| BR (1) | BR112018011073A2 (en) |
| CA (1) | CA3002422C (en) |
| EA (1) | EA201891420A1 (en) |
| HK (1) | HK1254755A1 (en) |
| MX (1) | MX2018007145A (en) |
| MY (1) | MY189425A (en) |
| PH (1) | PH12018501280A1 (en) |
| SG (2) | SG11201610812WA (en) |
| TW (3) | TW202231662A (en) |
| WO (1) | WO2017104783A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3056568T3 (en) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES |
| CN106519025B (en) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | Method for changing isoelectric point of antibody by using amino acid substitution of CDR |
| KR102469853B1 (en) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| AU2011337704B2 (en) | 2010-11-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| DK2857420T3 (en) | 2012-05-30 | 2020-11-23 | Chugai Pharmaceutical Co Ltd | TARGET TISSUE SPECIFIC ANTIGIN BINDING MOLECULE |
| SG10201709559PA (en) | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| SG11201604495PA (en) | 2013-12-04 | 2016-07-28 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
| PE20221834A1 (en) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | ANTIMYOSTATIN ANTIBODIES |
| KR20170110129A (en) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use |
| AU2016372934B2 (en) * | 2015-12-18 | 2023-10-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| KR102456739B1 (en) * | 2016-06-17 | 2022-10-19 | 추가이 세이야쿠 가부시키가이샤 | Anti-myostatin antibodies and methods of use |
| CN116251182A (en) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
| CA3052837A1 (en) | 2017-02-28 | 2018-09-07 | Seattle Genetics, Inc. | Cysteine mutated antibodies for conjugation |
| WO2020032230A1 (en) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | Anti-cd137 antigen-binding molecule and utilization thereof |
| SG11202110986YA (en) | 2019-04-10 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Method for purifying fc region-modified antibody |
| RU2750267C1 (en) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Recombinant growth differentiation factor 11 (gdf11), a method for its production, an injectable drug for increasing the muscle mass of mammals and poultry as well as a method of using the drug |
| TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
| WO2023057404A1 (en) | 2021-10-06 | 2023-04-13 | F. Hoffmann-La Roche Ag | Novel combined administration |
| WO2023187022A1 (en) | 2022-04-01 | 2023-10-05 | F. Hoffmann-La Roche Ag | New treatment for facioscapulohumeral muscular dystrophy (fshd) |
| US11780910B1 (en) | 2022-05-02 | 2023-10-10 | Novo Nordisk A/S | Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration |
| WO2024081932A1 (en) | 2022-10-14 | 2024-04-18 | Genentech, Inc. | Methods for treating spinal muscular atrophy |
| CN116990528B (en) * | 2023-09-27 | 2024-02-06 | 成都华西海圻医药科技有限公司 | Analysis method for rapidly determining anti-CD40 monoclonal antibody based on Gyrolab platform |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| AR047392A1 (en) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES |
| US7442778B2 (en) * | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| PL2066695T3 (en) * | 2006-09-05 | 2013-08-30 | Lilly Co Eli | Anti-myostatin antibodies |
| PE20091163A1 (en) * | 2007-11-01 | 2009-08-09 | Wyeth Corp | ANTIBODIES FOR GDF8 |
| KR102469853B1 (en) | 2008-04-11 | 2022-11-22 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| UY32341A (en) * | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | NEW ANTIGEN UNION PROTEINS |
| WO2011111007A2 (en) * | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| AR081556A1 (en) * | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | HUMANIZED ANTIGEN UNION PROTEINS |
| CN107827979A (en) * | 2012-03-16 | 2018-03-23 | 瑞泽恩制药公司 | The engineered light chain antibody of histidine and the non-human animal through genetic modification for generating the antibody |
| TWI619729B (en) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | Anti-hla-b*27 antibodies and uses thereof |
| WO2014028354A1 (en) * | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| SG10201709559PA (en) * | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| SG10201913751RA (en) * | 2013-05-06 | 2020-03-30 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
| CN105960414A (en) * | 2013-08-14 | 2016-09-21 | 诺华股份有限公司 | Methods of treating sporadic inclusion body myositis |
| WO2016073879A2 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| CA3005158A1 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| PE20221834A1 (en) * | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | ANTIMYOSTATIN ANTIBODIES |
| AU2016372934B2 (en) | 2015-12-18 | 2023-10-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
-
2016
- 2016-12-16 AU AU2016372934A patent/AU2016372934B2/en active Active
- 2016-12-16 MX MX2018007145A patent/MX2018007145A/en unknown
- 2016-12-16 CN CN201680072782.7A patent/CN108473562B/en active Active
- 2016-12-16 MY MYPI2018702306A patent/MY189425A/en unknown
- 2016-12-16 TW TW110149330A patent/TW202231662A/en unknown
- 2016-12-16 JP JP2016244254A patent/JP6142069B1/en active Active
- 2016-12-16 BR BR112018011073A patent/BR112018011073A2/en active Search and Examination
- 2016-12-16 SG SG11201610812WA patent/SG11201610812WA/en unknown
- 2016-12-16 EA EA201891420A patent/EA201891420A1/en unknown
- 2016-12-16 WO PCT/JP2016/087487 patent/WO2017104783A1/en active Application Filing
- 2016-12-16 SG SG10201707267RA patent/SG10201707267RA/en unknown
- 2016-12-16 KR KR1020177003241A patent/KR101820637B1/en active IP Right Grant
- 2016-12-16 TW TW105141729A patent/TWI605057B/en active
- 2016-12-16 KR KR1020237005092A patent/KR20230027321A/en not_active Application Discontinuation
- 2016-12-16 TW TW106129765A patent/TWI749057B/en active
- 2016-12-16 CN CN202210678733.5A patent/CN115028721A/en active Pending
- 2016-12-16 CA CA3002422A patent/CA3002422C/en active Active
- 2016-12-16 KR KR1020187001235A patent/KR102501335B1/en active IP Right Grant
- 2016-12-16 EP EP16875757.3A patent/EP3390443A4/en active Pending
- 2016-12-16 AR ARP160103887A patent/AR107078A1/en unknown
-
2017
- 2017-05-08 JP JP2017092151A patent/JP7053164B2/en active Active
-
2018
- 2018-06-14 PH PH12018501280A patent/PH12018501280A1/en unknown
- 2018-10-29 HK HK18113798.7A patent/HK1254755A1/en unknown
-
2022
- 2022-03-31 JP JP2022058710A patent/JP2022097485A/en active Pending
-
2023
- 2023-11-29 JP JP2023201204A patent/JP2024023427A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501280A1 (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use | |
| MX2023001834A (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use. | |
| MX2023007211A (en) | Anti-myostatin antibodies and methods of use. | |
| MX2022001222A (en) | Anti-tim-3 antibodies and methods of use thereof. | |
| SG10201909716RA (en) | Modified j-chain | |
| MX2017014397A (en) | Anti-fcrn antibodies. | |
| SG10201909180SA (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| PH12016501689A1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| MX2019013124A (en) | Uti fusion proteins. | |
| PH12020550483A1 (en) | Anti-apoc3 antibodies and methods of use thereof | |
| MX2015012281A (en) | Improved tnf binding proteins. | |
| MX2018003445A (en) | Expression of fc-containing proteins. | |
| KR20240058997A (en) | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |